Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26341
Title: Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
Austin Authors: Klein, Oliver ;Kee, Damien ;Markman, Ben;Carlino, Matteo S;Underhill, Craig;Palmer, Jodie ;Power, Daniel;Cebon, Jonathan S ;Behren, Andreas
Affiliation: Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, Australia
Monash University, Melbourne, Australia
Department of Medical Oncology, Alfred Health, Melbourne, Australia
Olivia Newton-John Cancer Research Institute
Blacktown Hospital and the University of Sydney, Sydney, Australia
Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, Australia
Medical Oncology
School of Cancer Medicine, La Trobe University, Australia
ThermoFisher Scientific Ltd
Issue Date: 29-Apr-2021
Date: 2021-05-10
Publication information: Cancer Cell 2021; 39(5): 592-593
URI: https://ahro.austin.org.au/austinjspui/handle/1/26341
DOI: 10.1016/j.ccell.2021.04.005
Journal: Cancer Cell
PubMed URL: 33930312
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

42
checked on Jul 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.